Compare Crowdstrike Holdings Inc (CRWD) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crowdstrike Holdings Inc vs Johnson & Johnson — how do they compare? Crowdstrike Holdings Inc trades at $275.04 (market cap $269.31B), while Johnson & Johnson trades at $261.44 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 2.3× Crowdstrike Holdings Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while Crowdstrike Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crowdstrike Holdings Inc for 97 Days and Johnson & Johnson for 129 Days on average.
| CRWD | JNJ | |
|---|---|---|
Market Cap | $269.31B | $618.09B |
Volume | 9,381,560 | 6,050,983 |
Sector | Technology | Health |
52-Week High | $278.86 | $278.43 |
52-Week Low | $87.56 | $186.00 |
Typical Hold Time | 97 Days | 129 Days |
Enterprise Value | $265.11B | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CrowdStrike (CRWD) trades at $263.01, down 0.92% on the day but near its 52-week high of $267.69. The stock shows strong technical momentum with bullish moving averages and has consistently beaten earnings expectations in recent quarters. Revenue growth remains robust, reaching $3.95 billion in 2025, though profitability metrics show modest net income margins. Analyst sentiment is overwhelmingly positive with 76% buy ratings and a consensus price target of $235.74.
CrowdStrike presents a compelling growth story with strong revenue expansion and AI-driven cybersecurity demand, but faces valuation concerns with elevated P/S and P/B ratios. The company's integration with OpenAI Marketplace and identity business growth provide catalysts, while competitive pressures and execution risks remain key considerations for investors.
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).
JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crowdstrike Holdings Inc
CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
